Bendamustine

• Description:

  Bendamustine (SDX-105 free base), a purine analogue, is a DNA cross-linking agent. Bendamustine activates DNA-damage stress response and apoptosis. Bendamustine has potent alkylating, anticancer and antimetabolite properties[1].

• Product Name Alternative:

  SDX-105 (free base)

• UNSPSC:

  12352005

• Hazard Statement:

  H301, H311, H331, H341

• Target:

  Apoptosis; DNA Alkylator/Crosslinker

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Bendamustine.html

• Purity:

  98.0

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(O)CCCC1=NC2=CC(N(CCCl)CCCl)=CC=C2N1C

• Molecular Formula:

  C16H21Cl2N3O2

• Molecular Weight:

  358.26

• Precautions:

  H301, H311, H331, H341

• References & Citations:

  [1]Leoni LM, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008 Jan 1;14 (1) :309-17.|[2]Cives M, et al. Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cell Signal. 2013 May;25 (5) :1108-17.|[3]Ackler S, et al. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo. Br J Pharmacol. 2012 Oct;167 (4) :881-91.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Citation 01:

  Leukemia. 2023 Nov;37 (11) :2221-2230.|Cell Rep Med. 2025 Apr 2:102053.|J Biomed Res. 2017 0 (0) : 1-12.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Patent. US20160222465A1.

• CAS Number:

  [16506-27-7]